Turquoise Health Snags $40M to Simplify Healthcare Contracts & Payments
Katie Adams / medcitynews - Turquoise Health raised $40 million in a Series C round to expand beyond price transparency into managing healthcare contracts. The startup’s platform aims to simplify payer–provider agreements, reduce administrative waste and enable patients to see guara…
AI Summary: Turquoise Health closed a $40 million funding round to accelerate its platform that standardizes healthcare contracts and payments, aiming to increase price transparency and streamline payer–provider interactions. The cash infusion will support product growth, sales expansion and the company's push to make messy contract data slightly less catastrophic for hospital finance teams.
Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center
oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]
AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.
Why Providence Wants to Sell Its Health Plan
Katie Adams / medcitynews - Providence announced its intent to sell its health plan, exiting the “payvider” model as rising costs and operational complexity weigh on smaller regional insurers. The move reflects a broader trend of health systems refocusing on core care delivery and e…
AI Summary: Providence Healthcare is actively weighing the sale of its health insurance arm as mounting fiscal pressures force leaders to consider dramatic options. The move would reshape the system’s payer-provider footprint, potentially easing balance‑sheet strain while unnerving patients, employers and regulators who’ll suddenly have a stake in the decision.
Lantern Secures $30M to Fuel Growth Across Employers and Health Plans
Marissa Plescia / medcitynews - Lantern’s $30 million raise was led by Morgan Health, a JPMorganChase business unit focused on employer-sponsored healthcare, as well as Echo Health Ventures, a strategic investment platform that invests on behalf of multiple Blues health plans.The post L…
AI Summary: Lantern secured a $30 million investment led by Morgan Health and Echo Health Ventures to scale its employer- and plan-facing digital health platform. The capital will accelerate product development, deepen payer-employer partnerships, and expand deployment of Lantern’s care navigation and benefits tools as it chases broader market traction — because nothing says progress like more tech for paperwork.
Sutter, Allina Health Combine to Form $26B Health System
Katie Adams / medcitynews - Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising …
AI Summary: Sutter Health and Allina Health have agreed to combine in a transaction that would create a $26 billion nonprofit system spanning California and Minnesota, forming a 39‑hospital network. The deal aims to consolidate operations and expand market reach, subject to definitive agreements and regulatory approvals, promising scale-driven efficiencies — and inevitably, some rebranded parking lots.
- Close watch: finances, approvals and expected closing timeline (2)
- On the ground: Sutter and Allina agree to $26B merger (3)
- Other developments: regional hospital expansions and financing moves (2)
- Trend watch: consolidation reshaping hospital markets nationwide (2)
- All Other Stories
Close watch: finances, approvals and expected closing timeline
On the ground: Sutter and Allina agree to $26B merger
Other developments: regional hospital expansions and financing moves
Trend watch: consolidation reshaping hospital markets nationwide
All Other Stories
‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug
Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…
AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.
'Leaky' brain barrier revealed as driver of chronic brain damage in retired combat and collision sports athletes
medicalxpress - Research, led by teams at Trinity College Dublin and the FutureNeuro Research Ireland Center, has pinpointed the mechanism linking some sports injuries to poor brain health in retired athletes. The research, published in Science Translational Medicine, ha…
AI Summary: New research links repetitive head impacts in contact and combat sports to blood–brain barrier breakdown, which appears to drive chronic traumatic encephalopathy and progressive cognitive decline. The studies identify vascular leakage as a key mechanism and suggest that strategies to bolster the barrier could reduce long-term brain damage in athletes and veterans.
Britain rushes to contain deadly meningitis outbreak
medicalxpress - Over 10 people were hospitalized in the UK and students urged to take preventative antibiotics Tuesday as health officials rushed to treat a deadly meningitis outbreak linked to a nightclub.
AI Summary: Health officials in southern England have mounted an urgent response to a fast‑moving meningococcal outbreak tied to student nightlife in Kent, after multiple hospitalizations and at least two deaths. Authorities are offering antibiotics, assessing vaccine policy for teens, and urging vigilance as contact tracing and public health measures try to stop transmission before more young people fall ill.
- Human stories: parents and survivors recount meningitis's devastation (5)
- Live from Kent: explosive student meningitis outbreak and response (14)
- Other coverage: science, trials and unrelated tech pieces (9)
- Policy spotlight: why teens missed MenB vaccine, debate intensifies (6)
- All Other Stories
Human stories: parents and survivors recount meningitis's devastation
Live from Kent: explosive student meningitis outbreak and response
Other coverage: science, trials and unrelated tech pieces
Policy spotlight: why teens missed MenB vaccine, debate intensifies
All Other Stories
Bluesky Mentions: @justinhendrix.bsky.social
Federal court blocks RFK Jr.’s moves to upend US vaccine policy
Delilah Alvarado / healthcaredive - The ruling, related to a lawsuit from several major medical organizations, said that HHS ignored established protocols when altering the childhood immunization schedule and overhauling a key CDC panel.
AI Summary: A federal judge blocked actions by an HHS official seeking to alter longstanding childhood vaccine policies, ruling the department failed to follow established procedures. The decision reaffirms agency protocol for vaccine recommendations and curbs abrupt unilateral policy shifts, restoring a measure of regulatory due process.
- Courts curb HHS unilateral actions across vaccines and gender care (6)
- HHS leadership chaos and White House reining in RFK Jr. (3)
- States push back, setting their own vaccine policies (1)
- All Other Stories
Courts curb HHS unilateral actions across vaccines and gender care
HHS leadership chaos and White House reining in RFK Jr.
States push back, setting their own vaccine policies
All Other Stories
New EPA rule could loosen limits on medical device sterilization gas emissions
medicalxpress - The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.
AI Summary: The Environmental Protection Agency proposed easing limits on ethylene oxide — the gas hospitals use to sterilize medical devices — arguing the change protects the medical supply chain. Public‑health experts and community advocates warn long‑term exposure raises cancer risks and say rolling back 2024 safeguards could shift the burden onto nearby residents.
Officials examine deaths after plasma donations in Winnipeg
medicalxpress - Canadian health officials are investigating the deaths of two people who donated plasma at private clinics in Winnipeg, Manitoba.
AI Summary: Health officials are investigating the deaths of two people who recently donated plasma at for‑profit clinics in Winnipeg, prompting scrutiny of donation frequency, screening practices and clinic oversight. Regulators are reviewing protocols and collecting evidence as public health teams work to determine whether systemic safety failures or procedural lapses contributed to the fatalities.
Healthcare tech inovation: Lessons from HIMSS 2026
healthcaredive - At HIMSS 2026, AWS took the stage with Jupiter Medical Center and Rady Children's Health. Read the key lessons from last week's Views from the Top Session.
AI Summary: At HIMSS 2026 vendors and health systems traded demos and earnest promises about real‑time data, cloud pathology and tighter interoperability — with AWS onstage alongside Jupiter Medical Center and Rady Children’s. The practical message: better connectivity and identity tools could finally unstick silos — if hospitals can stomach the integration bill.
- EHR rollouts: Epic expansions, VA launches and outages (6)
- HIMSS: Vendors push real-time data, cloud and interoperability (7)
- Interoperability drama: identity gaps, APIs and improper data access (7)
- OTHER: AI, imaging, workforce and operational healthcare stories (23)
- All Other Stories
EHR rollouts: Epic expansions, VA launches and outages
HIMSS: Vendors push real-time data, cloud and interoperability
Interoperability drama: identity gaps, APIs and improper data access
OTHER: AI, imaging, workforce and operational healthcare stories
All Other Stories
Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
Trial finds vitamin D supplements don't reduce COVID severity but could reduce long COVID risk
medicalxpress - In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.
AI Summary: A large randomized trial found high‑dose vitamin D3 did not lower acute COVID‑19 severity but revealed a surprising signal: supplementation may reduce the risk of developing long‑COVID. The result complicates the vitamin D narrative — not a cure, perhaps a modest shield against persistent post‑infectious symptoms worthy of further investigation.
NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.
FDA Drug Approval Marks a First for a Disease — But It’s Not Autism
Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …
AI Summary: The FDA has granted traditional approval to leucovorin for cerebral folate deficiency, formalizing a decades‑old generic’s role in a rare metabolic disorder. The decision comes amid earlier agency notes that evidence for autism benefit was weak and debate over expanding use without fresh trial data — cue the policy hot takes.
A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
- HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer (3)
- New insights into why aggressive breast cancers grow and spread (3)
- OTHER: related cancer research and approvals outside this TNBC angle (5)
- All Other Stories
HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer
New insights into why aggressive breast cancers grow and spread
OTHER: related cancer research and approvals outside this TNBC angle
All Other Stories
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.
Roche’s big hope breast cancer drug fails in crucial first-line trial
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.